A006620 Stock Overview
Manufactures and sells pharmaceuticals in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
My Notes
Capture your thoughts, links and company narrative
DongKoo Bio & Pharma Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩4,850.00 |
| 52 Week High | ₩8,990.00 |
| 52 Week Low | ₩4,300.00 |
| Beta | 0.73 |
| 1 Month Change | -4.90% |
| 3 Month Change | -18.35% |
| 1 Year Change | -13.08% |
| 3 Year Change | -39.83% |
| 5 Year Change | -13.39% |
| Change since IPO | -62.21% |
Recent News & Updates
DongKoo Bio & Pharma (KOSDAQ:006620) Has A Pretty Healthy Balance Sheet
Dec 16
More Unpleasant Surprises Could Be In Store For DongKoo Bio & Pharma Co., Ltd.'s (KOSDAQ:006620) Shares After Tumbling 32%
Aug 23Recent updates
DongKoo Bio & Pharma (KOSDAQ:006620) Has A Pretty Healthy Balance Sheet
Dec 16More Unpleasant Surprises Could Be In Store For DongKoo Bio & Pharma Co., Ltd.'s (KOSDAQ:006620) Shares After Tumbling 32%
Aug 23Should You Be Adding DongKoo Bio & Pharma (KOSDAQ:006620) To Your Watchlist Today?
Jul 25We Think That There Are Issues Underlying DongKoo Bio & Pharma's (KOSDAQ:006620) Earnings
Mar 27Shareholder Returns
| A006620 | KR Pharmaceuticals | KR Market | |
|---|---|---|---|
| 7D | -1.6% | -0.5% | -1.9% |
| 1Y | -13.1% | 0.8% | -9.5% |
Return vs Industry: A006620 underperformed the KR Pharmaceuticals industry which returned 2.4% over the past year.
Return vs Market: A006620 underperformed the KR Market which returned -9% over the past year.
Price Volatility
| A006620 volatility | |
|---|---|
| A006620 Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.8% |
| 10% least volatile stocks in KR Market | 3.3% |
Stable Share Price: A006620 has not had significant price volatility in the past 3 months compared to the KR market.
Volatility Over Time: A006620's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1970 | 381 | Cho Yong-Jun | www.dongkoo.com |
DongKoo Bio & Pharma Co., Ltd. manufactures and sells pharmaceuticals in South Korea. The company provides prescription drugs, such as antihistamines, dermatological oral medications, ophthalmic solutions, skeletal muscle relaxants, anti-inflammatory enzymes, antivirals, antibacterial agents, and for the treatment of allergies, liver diseases, mental illnesses, obesity, brain nervous, and endocrine systems; over-the-counter medicines, such as dermatological external preparations, antifungal agents, active probiotic intestinal supplements, antipyretic anti-inflammatory analgesics, and for the treatment of the respiratory, digestive, genitourinary, and circulatory systems; and quasi-drugs.
DongKoo Bio & Pharma Co., Ltd. Fundamentals Summary
| A006620 fundamental statistics | |
|---|---|
| Market cap | ₩132.41b |
| Earnings (TTM) | ₩15.34b |
| Revenue (TTM) | ₩253.71b |
8.6x
P/E Ratio0.5x
P/S RatioIs A006620 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A006620 income statement (TTM) | |
|---|---|
| Revenue | ₩253.71b |
| Cost of Revenue | ₩98.51b |
| Gross Profit | ₩155.20b |
| Other Expenses | ₩139.86b |
| Earnings | ₩15.34b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 561.74 |
| Gross Margin | 61.17% |
| Net Profit Margin | 6.05% |
| Debt/Equity Ratio | 64.5% |
How did A006620 perform over the long term?
See historical performance and comparisonDividends
2.5%
Current Dividend Yield21%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/25 08:16 |
| End of Day Share Price | 2024/12/24 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
DongKoo Bio & Pharma Co., Ltd. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Hyung Soo Kim | Cape Investment & Securities Co., Ltd. |
| Kwan Jun Ra | NH Investment & Securities Co., Ltd. |